https://www.selleckchem.com/sc....reening/fda-approved
Doxorubicin-loaded LifePearl™ TACE might be an effective treatment, with a good safety profile, for patients with early/intermediate-stage hepatocellular carcinoma. Further prospective data, especially with a small cohort of selected patients, are required to confirm these results. To examine the locoregional therapy (LRT) patterns and the healthcare economic burden of patients with hepatocellular carcinoma (HCC) in theUSA. Patients with newly diagnosed HCC were identified from the MarketScan databases (1 July 2015-31
Beğen
Yorum Yap
Paylaş
